Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy : A randomized phase III trial - COnCERTO (French 01-18) 2019/0407/HP

Phase 3

Recruiting

• Conditions: patients admitted for an obstructive colon cancer

• Registration Number: 2024-516456-17-00
• Lead Sponsor: Centre Hospitalier Universitaire Rouen

Brief Summary

determine whether CAPOX or FOLFOX neoadjuvant chemotherapy in a perioperative strategy in patients admitted for an OCC (and for whom occlusion was lifted by a discharge stoma), may improve the rate of complete curative therapeutic sequence as compared to an adjuvant chemotherapy strategy.

Detailed Description

In France, for patients admitted for an obstructive colon cancer, surgery is the preferred strategy. Primary diverting stoma is associated with low morbidity, and low 30-day mortality. Primary diverting stoma is not a major surgical undertaken, is effective to relief bowel obstruction, enables optimization of the patient's condition, allows adequate oncological staging and secondary elective colectomy. This strategy is actually recommended by the French and European Guidelines in patients with left-sided obstructive colon cancer and may be an option in patients with right-sided obstructive colon cancer, especially in those at high risk of postoperative complications

Urgent surgery for obstructive colon cancer is associated with increased risk of postoperative morbidity, mortality and permanent stoma rates as it is generally performed in elderly patients with poor medical condition or in patients with severe comorbidities. Moreover, obstructive colon cancers are diagnosed at locally advanced (T4) or metastatic stage and, at equal tumour stage, obstruction itself negatively impacts oncological outcomes in colon cancer patients. Among the several factors that may explain poor oncological outcomes of OCC, the absence of adjuvant chemotherapy may play an important role.

Adjuvant chemotherapy is the standard of care for patients undergoing curative resection for a stage III CC. For those with MSS high-risk stage II CC, adjuvant treatment is still a matter of debate. However, in the particular setting of MSS stage II obstructing CC, adjuvant chemotherapy may improve oncological outcomes. Because of high postoperative morbidity and patients' medical conditions, up to 37% of OCC patients for whom adjuvant systemic chemotherapy is considered appropriate do not receive this treatment. It is our hypothesis that the initiation of chemotherapy before resection of the primary tumour in a perioperative setting in patients with non-metastatic OLCC and for whom the obstruction has been relieved by a colostomy may allow to treat a higher proportion of patients with a full curative therapeutic sequence (including resection and chemotherapy if needed).

Randomized phase II-III trials have demonstrated the feasibility (tolerance, postoperative morbidity) and the efficacy (tumor downstaging, tumor downsizing, histological regression, higher R0 resection rate) of neoadjuvant FOLFOX or CAPOX chemotherapy in uncomplicated colon cancer with a trend towards an improvement of DFS. Data of these studies led the French Oncological Authorities to accept neoadjuvant chemotherapy in a perioperative setting as a therapeutic option in patients with locally advanced colon cancer (TNCD 21/01/2019, chapter 3, Cancer du colon non métastatique (p10): "Neo-adjuvant chemotherapy may be considered for locally advanced tumors deemed unresectable or at the limit of resectability (expert opinion)"; "it is possible to perform an upstream stoma before starting chemotherapy ("neo-adjuvant") and then a re-intervention aimed at exeresis (expert opinion). This treatment option should be discussed at the preoperative multidisciplinary consultation meeting if a T4 tumor is suspected during the preoperative workup."

The authors concluded that neoadjuvant chemotherapy using FOLFOX was feasible and might be a treatment option for patients with obstructive colon cancer for whom the obstruction has been relieved by a definctioning stoma. Further large-scale studies are warranted to confirm the present findings. This is exactly what COnCERTO trial aims to determine.

It is our hypothesis that the initiation of neoadjuvant chemotherapy in a perioperative setting in patients with non-metastatic MSS/pMMR Obstructive Colon Cancer (OCC) and for whom the obstruction has been relieved by a stoma may improve the compliance of the treatment and thus may allow to increase the rate of patients receiving the full curative therapeutic sequence according to the guidelines defined as following:

Resection of the primary tumor WITH:

* Low-risk stage II: NO CHEMOTHERAPY

* High-risk stage II: CHEMOTHERAPY AT INVESTIGATOR'S DISCRETION

* Stage III pT1-T3N1: CAPOX (3 months) or FOLFOX (6 months)

* Stage III pT4 and/or N2: FOLFOX (6 months) MSS High-risk stage II are defined as following: No microsatellite instability and presence of vascular emboli, perinervous or lymphatic invasion, poor differentiation, \<12 harvested lymph nodes, perforation).

In addition, once OCC are known to have poor prognosis compared to their non-complicated counterparts, neoadjuvant chemotherapy (before resection of the primary) may improve prognosis of these patients by treating circulating micrometastases or by inducing tumor down-staging and thus improving the R0 resection rate.

We thus designed a randomized phase III trial aiming to assess whether FOLFOX or CAPOX neoadjuvant chemotherapy in a perioperative setting may increase the rate of full curative therapeutic sequence in patients with MSS/pMMR OCC first treated by a defunctionning stoma (figure 5).

Demonstrating the positive impact on complicance to the full curative therapic strategy of perioperative chemotherapy in patients with OCC treated by defunctioning stoma, may change medical practices at a national and international level and may lead to a new standard of care. OCC is a major public health issue with no improvement in prognosis during the past decade. By improving the compliance of treatment of patients with OCC, the present study will ensure public health and economic benefits

Study Timeline

• Study First Posted: 2024-09-26
• Last Update Posted: 2025-01-30

Recruitment & Eligibility

• Status: Ongoing, recruiting
• Sex: Not specified
• Target Recruitment: 232

Inclusion Criteria

1. Age ≥ 18 years

2. No history of colorectal cancer

3. No serious medical co-morbidity (uncontrolled inflammatory bowel disease, uncontrolled angina, recent [within the past 6 months] myocardial infarction, or another serious medical condition) judged to compromise ability to tolerate chemotherapy and/or surgery

4. women participating in the study, contraception is required during chemotherapy treatment and for 15 months after cessation of chemotherapy treatment a) For Women of childbearing potential an effective contraception is required and a negative blood pregnancy test by beta-HCG at inclusion and monthly pregnancy tests throughout the study until the end of systemic treatment exposure b) For women surgically sterile the absence of ovaries and/or uterus is confirmed. c) For postmenauposal women a confirmation diagnostic (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit) is required

5. For men participating in the study, contraception is required during the trial and for 12 months after stopping chemotherapy treatment

6. Patient able to comply with the study protocol, in the investigator’s judgment

7. Patient affiliated with, or beneficiary of a social security (health insurance) category

8. Person informed and having signed his consent

9. ECOG performance status 0 or 1

10. Patients with obstructive colon cancer treated by defunctioning stoma

11. Pathologically confirmed adenocarcinoma (≥10 cm from the anal verge) MSS/pMMR (microsatellite stable primary tumor) status

12. Patient requiring colectomy

13. Laboratory data including : White blood cell count ≥ 3.109 /L with Neutrophils ≥ 1,5.109 / L, Platelet count ≥ 100.109 / L, Hemoglobin ≥ 9 g/dL (5,6 mmol/L), Total bilirubin ≤ 1,5 x ULN (upper limit of normal), ASAT and ALAT ≤ 2,5 x ULN, Alkaline phosphatase ≤ 1,5 x ULN, Serum creatinine ≤ 1,5 x ULN (performed 10-15 days prior to randomization)

14. Non metastatic colon cancer on thoracic-abdomino-pelvis CT scan

15. no suspicion of 2nd colon cancer

16. No prior chemotherapy or abdominal or pelvic irradiation

Exclusion Criteria

1. Contraindication to colectomy and/or anesthesia 2. Rectal cancer located within 10 cm of the anal verge by endoscopy or under the peritoneal reflection at surgery or having received radiation therapy prior to surgery 3. Patient having received radiation therapy prior to surgery 4. Metastatic spread at baseline assessment (lung, liver, peritoneal) 5. History or current evidence on physical examination of central nervous system disease or; Peripheral neuropathy ≥ grade 1 common toxicity criteria for adverse events NCI-CTCAE (version 5.0) 6. Contraindication to study chemotherapy treatments 7. Presence of inflammatory bowel disease HNPCC syndrome or polyposis 8. Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia 9. Uracilemia ≥ 150 ng/ml (suggestive of complete DPD deficiency) 10. Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent 11. Any significant disease, which, in the investigator’s opinion, would exclude the patient from the study. 12. Patient is a pregnant (positive blood pregnancy test) or breastfeeding (lactating) woman or intending to become pregnant during the study and for at least 15 months after the chemotherapy treatment termination 13. Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision) 14. Simultaneous participation in another interventional research

2. Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent

3. Any significant disease, which, in the investigator’s opinion, would exclude the patient from the study.

4. Patient is a pregnant (positive blood pregnancy test) or breastfeeding (lactating) woman or intending to become pregnant during the study and for at least 15 months after the chemotherapy treatment termination

5. Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)

6. Simultaneous participation in another interventional research

7. Rectal cancer located within 10 cm of the anal verge by endoscopy or under the peritoneal reflection at surgery or having received radiation therapy prior to surgery

8. Patient having received radiation therapy prior to surgery

9. Metastatic spread at baseline assessment (lung, liver, peritoneal)

10. History or current evidence on physical examination of central nervous system disease or; Peripheral neuropathy ≥ grade 1 common toxicity criteria for adverse events NCI-CTCAE (version 5.0)

11. Contraindication to study chemotherapy treatments

12. Presence of inflammatory bowel disease HNPCC syndrome or polyposis

13. Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia

14. Uracilemia ≥ 150 ng/ml (suggestive of complete DPD deficiency)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
the success of a full curative therapeutic		the success of a full curative therapeutic

Secondary Outcome Measures

Name	Time	Method
Number of cycles administered of neoadjuvant chemotherapy	36 months	Number of cycles administered of neoadjuvant chemotherapy
Quality and completeness of the surgical excision	36 months	number of lymph nodes examined, completeness of the mesocolon, margins
Overall morbidity according to the Dindo classification	at 90 days postoperatively.	according to the Dindo classification
Neoadjuvant chemotherapy Adverse events	36 months	Adverse events (grade 3,4 and 5 toxicity) related to neoadjuvant chemotherapy including those related to the primary tumor
Rate of primary tumour resection	36 months	Rate of primary tumour resection
Quality of life evaluated using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC	at J0, week5 (FOLFOX)/week7 (CAPOX), week9 (FOLFOX) and every 6 months a year	using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC
adjuvant chemotherapy adverse events	36 months	Adverse events (grade 3, 4 and 5 toxicity) related to adjuvant chemotherapy including those related to the primary tumor
Overall mortality	at 3 years and mortality without stoma at 3 years.	mortality without relapse

Trial Locations

Locations (28)

Centre Hospitalier Universitaire Grenoble Alpes; 🇫🇷 Grenoble Cedex 9, France

Assistance Publique Hopitaux De Paris; 🇫🇷 Paris, France

Centre Hospitalier De Versailles; 🇫🇷 Le Chesnay Cedex, France

Centre Hospitalier Universitaire De Bordeaux; 🇫🇷 Pessac Cedex, France

Centre Hospitalier Regional De Marseille; 🇫🇷 Marseille, France

Centre Hospitalier Universitaire De Poitiers; 🇫🇷 Poitiers, France

Les Hopitaux Universitaires De Strasbourg; 🇫🇷 Strasbourg Cedex 2, France

Union Mut Gestion Groupe Hosp Mutualiste De Grenoble; 🇫🇷 Grenoble, France

Centre Hospitalier Universitaire De Toulouse; 🇫🇷 Toulouse Cedex 9, France

Institut De Cancerologie Strasbourg Europe; 🇫🇷 Strasbourg, France

Scroll for more (18 remaining)

Centre Hospitalier Universitaire Grenoble Alpes

🇫🇷Grenoble Cedex 9, France

bertrand TRILLING

Site contact

0476769377

BTrilling@chu-grenoble.fr